Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Resverlogix grants Shenzhen Hepalink rights to RVX208 in some Asian territories; right of first refusal in US

Executive Summary

Resverlogix Corp. has licensed Shenzhen Hepalink Pharmaceutical Co. Ltd. rights to develop its lead cardiovascular compound RVX208 in China, Hong Kong, Taiwan, and Macau.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies